Samuel C Mok

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/963287/publications.pdf

Version: 2024-02-01

161	12,490	23879 60	30277 107
papers	citations	h-index	g-index

166	166	166	16757
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 2021, 113, 1369-1378.	3.0	8
2	SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers, 2021, 13, 1777.	1.7	13
3	Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes. Cancers, 2021, 13, 3218.	1.7	2
4	Clear cell ovarian tumors display a unique tumor immune microenvironment. Gynecologic Oncology, 2021, 162, S110-S111.	0.6	1
5	Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. Cancers, 2020, 12, 118.	1.7	22
6	The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 509-519.	1.1	34
7	ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nature Communications, 2020, 11, 3546.	5.8	28
8	Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers, 2020, 12, 2436.	1.7	8
9	Pathogenesis and Clinical Management of Uterine Serous Carcinoma. Cancers, 2020, 12, 686.	1.7	20
10	Disabled-2: a positive regulator of the early differentiation of myoblasts. Cell and Tissue Research, 2020, 381, 493-508.	1.5	6
11	Expression of long noncoding RNAs in cancerâ€associated fibroblasts linked to patient survival in ovarian cancer. Cancer Science, 2020, 111, 1805-1817.	1.7	25
12	Systematic Identification of Druggable Epithelialâ€“Stromal Crosstalk Signaling Networks in Ovarian Cancer. Journal of the National Cancer Institute, 2019, 111, 272-282.	3.0	42
13	Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clinical Cancer Research, 2019, 25, 6417-6428.	3.2	39
14	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunology, Immunotherapy, 2019, 68, 1515-1526.	2.0	14
15	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. Nature Communications, 2019, 10, 4369.	5.8	18
16	An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer. , 2019, , .		2
17	Mobilization of Intracellular Calcium Stores and ERâ€Mitochondrial Coupling in Highâ€grade Serous Ovarian Cancer (HGSOC) Cells. FASEB Journal, 2019, 33, .	0.2	0
18	ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers, 2018, 10, 464.	1.7	28

#	Article	IF	Citations
19	Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. Cancers, 2018, 10, 57.	1.7	24
20	Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clinical Cancer Research, 2017, 23, 4473-4481.	3.2	96
21	Mesothelialâ€toâ€mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. Journal of Pathology, 2017, 242, 140-151.	2.1	83
22	Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis. Scientific Reports, 2017, 7, 10374.	1.6	33
23	Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight, 2017, 2, .	2.3	38
24	Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. Journal of Clinical Investigation, 2017, 128, 589-606.	3.9	105
25	ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells. Oncotarget, 2017, 8, 16951-16963.	0.8	82
26	Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules, 2016, 6, 3.	1.8	43
27	Letter from the New Editor-in-Chief. Cancers, 2016, 8, 9.	1.7	0
28	Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement. American Journal of Physiology - Cell Physiology, 2016, 311, C1040-C1047.	2.1	10
29	Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metabolism, 2016, 24, 685-700.	7.2	293
30	Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nature Communications, 2016, 7, 11150.	5.8	577
31	Pancreatic cancer-derived exosomes: new role in paraneoplastic syndromes?. Translational Cancer Research, 2016, 5, S697-S700.	0.4	1
32	Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis. American Journal of Physiology - Cell Physiology, 2015, 309, C444-C456.	2.1	272
33	KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1. Oncotarget, 2015, 6, 31702-31720.	0.8	27
34	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 2015, 6, 44551-44562.	0.8	37
35	Loss of LKB1 in highâ€grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. Cancer, 2014, 120, 3457-3468.	2.0	21
36	CAF reprogramming inhibits ovarian cancer progression. Cell Cycle, 2014, 13, 3783-3784.	1.3	26

#	Article	IF	Citations
37	Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nature Communications, 2014, 5, 5092.	5.8	112
38	Poor survival with wild-type TP53 ovarian cancer?. Gynecologic Oncology, 2013, 130, 565-569.	0.6	40
39	PAX2 Expression in Ovarian Cancer. International Journal of Molecular Sciences, 2013, 14, 6090-6105.	1.8	26
40	Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage, High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2013, 19, 809-820.	3.2	78
41	TGF-Î² Modulates Ovarian Cancer Invasion by Upregulating CAF-Derived Versican in the Tumor Microenvironment. Cancer Research, 2013, 73, 5016-5028.	0.4	315
42	Gene Expression Signature of Normal Cell-of-Origin Predicts Ovarian Tumor Outcomes. PLoS ONE, 2013, 8, e80314.	1.1	43
43	Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance. PLoS ONE, 2013, 8, e81859.	1.1	95
44	FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. Journal of Clinical Investigation, 2013, 123, 4435-4448.	3.9	76
45	Involvement of Disabledâ€2 in early myogenesis. FASEB Journal, 2013, 27, 524.3.	0.2	0
46	Identification of a Potential Ovarian Cancer Stem Cell Gene Expression Profile from Advanced Stage Papillary Serous Ovarian Cancer. PLoS ONE, 2012, 7, e29079.	1.1	87
47	Cancer-Associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer. Neoplasia, 2011, 13, 393-405.	2.3	136
48	The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated With Differentiation and Survival in Ovarian Cancer. American Journal of Surgical Pathology, 2011, 35, 904-912.	2.1	83
49	The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma. Gynecologic Oncology, 2011, 123, 13-18.	0.6	47
50	Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated Tumorigenesis. Cancer Prevention Research, 2011, 4, 463-470.	0.7	53
51	C Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin. Clinical Cancer Research, 2011, 17, 1065-1074.	3.2	44
52	Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE, 2011, 6, e21121.	1.1	71
53	Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecologic Oncology, 2010, 119, 114-120.	0.6	71
54	BRAF Mutation Is Rare in Advanced-Stage Low-Grade Ovarian Serous Carcinomas. American Journal of Pathology, 2010, 177, 1611-1617.	1.9	183

#	Article	IF	Citations
55	The Monkey, the Hen, and the Mouse: Models to Advance Ovarian Cancer Chemoprevention. Cancer Prevention Research, 2009, 2, 773-775.	0.7	9
56	RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecologic Oncology, 2009, 112, 325-330.	0.6	47
57	A Gene Signature Predictive for Outcome in Advanced Ovarian Cancer Identifies a Survival Factor: Microfibril-Associated Glycoprotein 2. Cancer Cell, 2009, 16, 521-532.	7.7	230
58	Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. International Journal of Cancer, 2009, 124, 1358-1365.	2.3	148
59	Novel antiâ€ffilaminâ€A antibody detects a secreted variant of filaminâ€A in plasma from patients with breast carcinoma and highâ€grade astrocytoma. Cancer Science, 2009, 100, 1748-1756.	1.7	38
60	PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Modern Pathology, 2009, 22, 1243-1250.	2.9	76
61	Aberrant Promoter Methylation of Sparc in Ovarian Cancer. Neoplasia, 2009, 11, 126-IN1.	2.3	81
62	Inflammatory Cytokine Tumor Necrosis Factor Î± Confers Precancerous Phenotype in an Organoid Model of Normal Human Ovarian Surface Epithelial Cells. Neoplasia, 2009, 11, 529-541.	2.3	48
63	Dynamic expression of Dab2 in the mouse embryonic central nervous system. BMC Developmental Biology, 2008, 8, 76.	2.1	20
64	Overexpression of laminin receptor 1 on decidual cells in partial and complete mole. Gynecologic Oncology, 2008, 108, 121-125.	0.6	7
65	Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecologic Oncology, 2008, 109, 234-239.	0.6	16
66	Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. New England Journal of Medicine, 2008, 359, 2641-2650.	13.9	633
67	Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer. Neoplasia, 2008, 10, 964-IN7.	2.3	50
68	Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer. Clinical Cancer Research, 2008, 14, 7667-7673.	3.2	113
69	S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Molecular Cancer Therapeutics, 2008, 7, 1993-2002.	1.9	57
70	Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients. Clinical Cancer Research, 2008, 14, 764-771.	3.2	57
71	Activation of Platelet-Activating Factor Receptor and Pleiotropic Effects on Tyrosine Phospho-EGFR/Src/FAK/Paxillin in Ovarian Cancer. Cancer Research, 2008, 68, 5839-5848.	0.4	70
72	Inhibition of Dab2 Expression with Antisense Oligodeoxynucleotides in Mouse Embryos. Neuroembryology and Aging, 2008, 5, 89-99.	0.1	1

#	Article	IF	Citations
73	Expression of Dab2, a Tumor Suppressor, in the Human Fetal Hippocampus and Neocortex. Neuroembryology and Aging, 2008, 5, 182-190.	0.1	1
74	Antigen-specific T cell immune response detected by skewed T cell receptor usage in normal placenta and complete molar pregnancy. Journal of reproductive medicine, The, 2008, 53, 528-34.	0.2	1
75	Immune cell profiling in intraplacental and postmolar choriocarcinomas. Journal of reproductive medicine, The, 2008, 53, 558-64.	0.2	2
76	Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. Journal of reproductive medicine, The, 2008, 53, 589-94.	0.2	7
77	Whole Genome Oligonucleotide-Based Array Comparative Genomic Hybridization Analysis Identified Fibroblast Growth Factor 1 As a Prognostic Marker for Advanced-Stage Serous Ovarian Adenocarcinomas. Journal of Clinical Oncology, 2007, 25, 2281-2287.	0.8	131
78	Claudin-4 Overexpression in Epithelial Ovarian Cancer Is Associated with Hypomethylation and Is a Potential Target for Modulation of Tight Junction Barrier Function Using a C-Terminal Fragment of Clostridium perfringens Enterotoxin. Neoplasia, 2007, 9, 304-314.	2.3	98
79	Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Review of Proteomics, 2007, 4, 121-131.	1.3	18
80	SPARC Inhibits LPA-Mediated Mesothelialâ€"Ovarian Cancer Cell Crosstalk. Neoplasia, 2007, 9, 23-35.	2.3	59
81	Etiology and Pathogenesis of Epithelial Ovarian Cancer. Disease Markers, 2007, 23, 367-376.	0.6	42
82	Biomarkers of Mucinous Tumors of the Ovary. Disease Markers, 2007, 23, 389-396.	0.6	4
83	Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecologic Oncology, 2007, 106, 311-317.	0.6	58
84	Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. Gynecologic Oncology, 2007, 107, 292-297.	0.6	18
85	Candidate Tumor-Suppressor Gene DLEC1 Is Frequently Downregulated by Promoter Hypermethylation and Histone Hypoacetylation in Human Epithelial Ovarian Cancer. Neoplasia, 2006, 8, 268-278.	2.3	75
86	Comparison of Osteopontin Expression in Endometrioid Endometrial Cancer and Ovarian Endometrioid Cancer. Medical Oncology, 2006, 23, 205-212.	1.2	11
87	PTEN expression in clear cell adenocarcinoma of the ovary. Gynecologic Oncology, 2006, 101, 71-75.	0.6	74
88	Clusterin confers paclitaxel resistance in cervical cancer. Gynecologic Oncology, 2006, 103, 996-1000.	0.6	24
89	Selenium binding protein 1 in ovarian cancer. International Journal of Cancer, 2006, 118, 2433-2440.	2.3	90
90	Proteomic-Based Discovery and Characterization of Glycosylated Eosinophil-Derived Neurotoxin and COOH-Terminal Osteopontin Fragments for Ovarian Cancer in Urine. Clinical Cancer Research, 2006, 12, 432-441.	3.2	147

#	Article	IF	Citations
91	Expression Profiling Identifies Altered Expression of Genes That Contribute to the Inhibition of Transforming Growth Factor-Î² Signaling in Ovarian Cancer. Cancer Research, 2006, 66, 8404-8412.	0.4	90
92	Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo. Cancer Research, 2006, 66, 7983-7990.	0.4	132
93	Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance. Clinical Cancer Research, 2006, 12, 690-700.	3.2	64
94	Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches. Advances in Cancer Research, 2006, 96, 1-22.	1.9	12
95	Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genetics and Cytogenetics, 2005, 159, 53-57.	1.0	36
96	Ovarian cancer is a heterogeneous disease. Cancer Genetics and Cytogenetics, 2005, 161, 170-173.	1.0	39
97	Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecologic Oncology, 2005, 96, 77-83.	0.6	60
98	Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology, 2005, 99, 267-277.	0.6	324
99	Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics, 2005, 5, 3183-3192.	1.3	44
100	Identification of Overexpression and Amplification of ABCF2 in Clear Cell Ovarian Adenocarcinomas by cDNA Microarray Analyses. Clinical Cancer Research, 2005, 11, 6880-6888.	3.2	70
101	Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas. Clinical Cancer Research, 2005, 11, 7651-7657.	3.2	19
102	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Cancer Research, 2005, 65, 2162-2169.	0.4	484
103	Epigenetic Silencing of Cellular Retinol-Binding Proteins in Nasopharyngeal Carcinoma. Neoplasia, 2005, 7, 67-74.	2.3	39
104	Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary. Cancer Research, 2005, 65, 10602-10612.	0.4	298
105	Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review. Disease Markers, 2004, 20, 53-70.	0.6	63
106	Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer. Clinical Cancer Research, 2004, 10, 3474-3478.	3.2	85
107	DNA copy number abnormality of oral squamous cell carcinoma detected with cDNA array-based comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2004, 151, 90-92.	1.0	9
108	Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genetics and Cytogenetics, 2004, 151, 82-84.	1.0	29

#	Article	IF	Citations
109	Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genetics and Cytogenetics, 2004, 155, 97-107.	1.0	32
110	Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Human Genetics, 2004, 115, 327-30.	1.8	79
111	Molecular biology of gestational trophoblastic neoplasia: a review. Journal of reproductive medicine, The, 2004, 49, 415-22.	0.2	13
112	Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cellsâ˜†â˜†The authors have no connection to any companies or products mentioned in this article.. Gynecologic Oncology, 2003, 88, 424-428.	0.6	44
113	Osteopontin is down-regulated in hydatidiform mole. Gynecologic Oncology, 2003, 89, 134-139.	0.6	14
114	Prostate carcinoma tissue proteomics for biomarker discovery. Cancer, 2003, 98, 2576-2582.	2.0	82
115	Disruption of the Fanconi anemiaâ€“BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Medicine, 2003, 9, 568-574.	15.2	508
116	New technologies for the identification of markers for early detection of ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2003, 15, 51-55.	0.9	43
117	Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clinical Cancer Research, 2003, 9, 2904-11.	3.2	208
118	Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. Anticancer Research, 2003, 23, 3151-7.	0.5	9
119	Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clinical Cancer Research, 2003, 9, 4782-91.	3.2	61
120	Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clinical Cancer Research, 2003, 9, 4811-8.	3.2	73
121	Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1671.	3.8	391
122	Reproductive Hormone-Induced, STAT3-Mediated Interleukin 6 Action in Normal and Malignant Human Ovarian Surface Epithelial Cells. Journal of the National Cancer Institute, 2002, 94, 617-629.	3.0	117
123	BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome. Cell, 2002, 111, 393-405.	13.5	283
124	Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes and Cancer, 2002, 33, 123-132.	1.5	24
125	Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy. Diseases of the Colon and Rectum, 2002, 45, 1242-1248.	0.7	45
126	Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Research, 2002, 62, 3058-62.	0.4	29

#	Article	IF	Citations
127	Recent advances in molecular biology of gestational trophoblastic diseases. A review. Journal of reproductive medicine, The, 2002, 47, 369-79.	0.2	14
128	Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Research, 2002, 62, 6218-23.	0.4	39
129	Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clinical Cancer Research, 2002, 8, 3324-31.	3.2	94
130	Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Molecular Cancer Therapeutics, 2002, 1, 769-76.	1.9	92
131	SPARC (Secreted Protein Acidic and Rich in Cysteine) Induces Apoptosis in Ovarian Cancer Cells. American Journal of Pathology, 2001, 159, 609-622.	1.9	199
132	Identification of Differentially Expressed Genes from Ovarian Cancer Cells by MICROMAXâ„¢ cDNA Microarray System. BioTechniques, 2001, 30, 670-675.	0.8	85
133	k-ras Mutation May Be an Early Event in Mucinous Ovarian Tumorigenesis. International Journal of Gynecological Pathology, 2001, 20, 244-251.	0.9	66
134	Lysophospholipids Increase Interleukin-8 Expression in Ovarian Cancer Cells. Gynecologic Oncology, 2001, 81, 291-300.	0.6	113
135	DOC-2/hDab2 Expression Is Up-Regulated in Primary Pancreatic Cancer but Reduced in Metastasis. Laboratory Investigation, 2001, 81, 863-873.	1.7	26
136	DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. Oncogene, 2001, 20, 6960-6964.	2.6	51
137	Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology. Journal of the National Cancer Institute, 2001, 93, 1458-1464.	3.0	268
138	Altered expression ofBRCA1,BRCA2, and a newly identifiedBRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Molecular Carcinogenesis, 2000, 28, 236-246.	1.3	41
139	Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene, 2000, 19, 1885-1890.	2.6	58
140	Genetic Alterations of the WT1 Gene in Papillary Serous Carcinoma of the Peritoneum. Gynecologic Oncology, 2000, 76, 369-372.	0.6	36
141	ras Gene Activation and Infrequent Mutation in Papillary Serous Carcinoma of the Peritoneum. Gynecologic Oncology, 2000, 77, 105-111.	0.6	4
142	Expression of Epidermal Growth Factor Receptor-Related Family Products in Gestational Trophoblastic Diseases and Normal Placenta and Its Relationship with Development of Postmolar Tumor. Gynecologic Oncology, 2000, 77, 389-393.	0.6	62
143	Distinct Allelic Loss Patterns in Papillary Serous Carcinoma of the Peritoneum. American Journal of Clinical Pathology, 2000, 114, 93-99.	0.4	15
144	Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers. American Journal of Pathology, 2000, 156, 409-417.	1.9	152

#	Article	IF	Citations
145	Differential Expression of Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Protein and mRNA in Epithelial Ovarian Tumors. Gynecologic Oncology, 2000, 77, 369-376.	0.6	49
146	A new human topoisomerase III that interacts with SGS1 protein. Nucleic Acids Research, 1999, 27, 993-1000.	6.5	43
147	Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors. Oncogene, 1999, 18, 257-262.	2.6	11
148	Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. Oncogene, 1999, 18, 4640-4642.	2.6	34
149	Matrix Metalloproteinases and Their Inhibitors in Gestational Trophoblastic Diseases and Normal Placenta. Gynecologic Oncology, 1999, 75, 248-253.	0.6	49
150	Differential Gene Expression Pattern between Normal Human Trophoblast and Choriocarcinoma Cell Lines: Downregulation of Heat Shock Protein-27 in Choriocarcinoma in Vitro and in Vivo. Gynecologic Oncology, 1999, 75, 391-396.	0.6	31
151	A Population-Based Study of BRCA1 and BRCA2 Mutations in Jewish Women With Epithelial Ovarian Cancer. Obstetrics and Gynecology, 1999, 93, 34-37.	1.2	17
152	A novel 4â€‰cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas. Oncogene, 1998, 16, 555-559.	2.6	37
153	Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene, 1998, 16, 3455-3459.	2.6	25
154	DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene, 1998, 17, 419-424.	2.6	99
155	BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum. Obstetrics and Gynecology, 1998, 92, 596-600.	1.2	26
156	Characterization of Human Ovarian Surface Epithelial Cells Immortalized by Human Papilloma Viral Oncogenes (HPV-E6E7 ORFs). Experimental Cell Research, 1995, 218, 499-507.	1.2	191
157	Overexpression of the Protein Tyrosine Phosphatase, Nonreceptor Type 6 (PTPN6), in Human Epithelial Ovarian Cancer. Gynecologic Oncology, 1995, 57, 299-303.	0.6	39
158	p53 Gene Mutation in Human Borderline Epithelial Ovarian Tumors. Journal of the National Cancer Institute, 1994, 86, 1549-1551.	3.0	58
159	Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer. Gynecologic Oncology, 1994, 52, 247-252.	0.6	166
160	Molecular Characterization and Mapping of Murine Genes Encoding Three Members of the Stefin Family of Cysteine Proteinase Inhibitors. Genomics, 1993, 15, 507-514.	1.3	35
161	Transcriptional analyses of the gene region that encodes human histidyl-tRNA synthetase: identification of a novel bidirectional regulatory element. Gene, 1993, 131, 201-208.	1.0	8